Why partner with us?
OXB is an innovative leading viral vector specialist – Lenti, AAV, Adeno and beyond - focused on delivering life changing therapies to patients. We are the partner of choice for viral vector development scale-up, analytics and GMP bioprocessing. With state-of-the-art capabilities and facilities in both the UK and US we are able to harness the experience of our experts and deliver high quality services.
We have over 200,000 sq. ft. of manufacturing, laboratory and office space across six facilities. This includes:
- 94,000 sq. ft. of manufacturing capabilities, with a further 20,000+ sq. ft. fallow and available for flexible expansion in the future
- 32,000 sq. ft. of laboratory space, with planning permission granted to redevelop an existing site to provide next generation laboratory facilities
- 7 GMP manufacturing suites operating next generation single-use 200L and 1000L bioreactors
- 2 fill/finish suites
- Warehouse and cold chain facilities
Our facility near Boston, Massachusetts, US, has 91,000 sq. ft. covering full scope process development and GMP operations for Adeno-Associated Viruses (AAV).
The GMP suites operate three 500L bioreactors using a proprietary serum-free suspension process for early-stage clinical manufacturing via a proprietary ‘plug and play’ platform, the production process has proven scalability to 2000L in process development laboratories.
Oxford Biomedica owns an 80% share in Oxford Biomedica Solutions LLC, which operates the Boston Facility, with the remaining 20% share owned by Homology Medicines Inc.